TD Waterhouse Canada’s Traws Pharma TRAW Stock Holding History

TD Waterhouse Canada’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5	Closed	-$87	–	1966
2023 Q4	$87	Hold	5	–	–	﹤0.01%	1660
2023 Q3	$87	Buy	+5	New	+$114	﹤0.01%	1664

Other funds holding TRAW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TD Waterhouse Canada's TRAW Position: Q1 2024 in Review

TD Waterhouse Canada sold out of Traws Pharma (TRAW) in Q1 2024, closing a stake of 5 shares — an estimated $87 sold.

TD Waterhouse Canada first reported a position in TRAW in Q3 2023 and held it in 2 quarters. The position peaked at $87 in Q4 2023. 24 funds tracked by Wall St. Rank hold TRAW as of Q1 2024.

TD Waterhouse Canada reported no remaining Traws Pharma position as of Q1 2024 after selling out during the quarter.
TD Waterhouse Canada sold 5 Traws Pharma shares in Q1 2024, an estimated $87.
TD Waterhouse Canada first reported a position in Traws Pharma in Q3 2023 and held it in 2 quarters.
TD Waterhouse Canada's Traws Pharma position peaked at $87 in Q4 2023.
24 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2024.

Based on TD Waterhouse Canada's 13F filing for Q1 2024, filed 10 May 2024.